It is demonstrated that Ficd deletion mitigates the pathological decrease in myelin structural proteins and oligodendrocyte maturation factors, restoring levels of mature, myelinating oligodendrocytes and identifies FICD as a novel target for alleviating non-neuronal toxicity in SCA3.
Abstract
Spinocerebellar ataxia type 3 (SCA3) is an inherited, fatal neurodegenerative disease caused by a pathological CAG repeat expansion in the ATXN3 gene, resulting in the selective degeneration of vulnerable neuronal populations. Recent work has identified impairments in oligodendrocyte maturation as a novel and robust feature of SCA3 pathogenesis. Oligodendrocytes synthesize myelin structural components through the endoplasmic reticulum (ER), rendering this organelle essential for white matter integrity. Despite this, the role of ER function in SCA3 remains unclear. In this study, we show that loss of FICD-mediated AMPylation, a post-translational modification regulating the ER-resident HSP70 chaperone, BiP, rescues motor impairments in a transgenic SCA3 mouse model. Ficd-/- SCA3 mice exhibit significantly reduced levels of nuclear ATXN3 in vulnerable brain regions, while Ficd+/+ littermates show an increased burden of AMPylated BiP in the spinal cord, identifying aberrant AMPylation as a novel contributor of SCA3 pathology. Using unbiased proteomics, we demonstrate that Ficd deletion mitigates the pathological decrease in myelin structural proteins and oligodendrocyte maturation factors, restoring levels of mature, myelinating oligodendrocytes. In parallel, we show that Ficd activates SREBP2-dependent cholesterol biosynthesis to support myelination. Taken as a whole, these findings posit ER homeostasis as a critical driver of oligodendrocyte pathology and identify FICD as a novel target for alleviating non-neuronal toxicity in SCA3.
It is shown that oligodendroglial Cit-k loss and the resulting hypomyelination are sufficient to produce long-lasting neurological and behavioral impairments independently of primary neuronal defects.
Martino Bonato, F. Marchiotto, Maryam Khastkhodaei Ardakani et al.· bioRxiv· 0 citations
LRRK2 G2019S mutation is the most common genetic cause of Parkinson's disease (PD) producing clinical manifestations similar to sporadic PD patients, hinting at the relevance of this mutation in the pathophysiological mechanisms of the disease. However, its role potentiating nigrostriatal neurodegeneration, particularl...
Roberto García-Swinburn, Laura Morón-Márquez, Carmen Conde-Naranjo et al.· Journal of Neurochemistry· 0 citations
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease, leading to progressive muscle weakness and motor impairment. Growing evidence indicates that cerebellar Purkinje cells, which play a central role in motor coordination, are also affected in ALS. However, it is unclear whether the molecular events that initi...
Katarina Maksimović, Rambabu Majji, Jhune Rizsan Santos et al.· bioRxiv· 0 citations
ABSTRACT Spinocerebellar ataxia type 3, also known as Machado–Joseph disease (MJD), is a fatal neurodegenerative disease caused by an expanded CAG repeat in ataxin-3 (ATXN3). Here, we investigated mitochondrial alterations across complementary MJD models, including transgenic zebrafish, CMVMJD135 mice and primary neuro...
Ignacio Simó, Katherine J. Robinson, Julia Y. Kam et al.· Disease Models & Mechanisms· 1 citation
These findings establish CBLN1 deficiency as a cause of hereditary ataxia and identify extracellular CBLN1 replacement as a therapeutic strategy for a reversible cerebellar synaptopathy.
Tokiwa Yamasak, W. Kakegawa, Ayumi Hayashi et al.· Molecular Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.